There is an appeal process now. I've observed that every time, with maybe one or two exceptions, we recommended that a drug not be funded, it was appealed, and we reviewed that appeal.
I would agree that the appeal should be more transparent and open, but that would mean the pharmaceutical companies would have to agree to allow all the information they submit to the CDR, which they frequently ask us to keep confidential, be open and public. I would be very supportive of that.